ALVO

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.43
Percentage change -5.14	%

Peers: ABBV PFE MRK LLY AMGN BIIB VRTX GILD REGN BMY

| Held by: IBB IBBQ BIB PRFZ GLCR STXK RFLR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.85	Insider Own	63.90%	Shs Outstand	301.81M	Perf Week	-4.22%
Market Cap	2.40B	Forward P/E	8.10	EPS next Y	0.98	Insider Trans	0.00%	Shs Float	108.97M	Perf Month	-31.26%
Income	-231.86M	PEG	-	EPS next Q	-0.11	Inst Own	5.22%	Short Float	0.73%	Perf Quarter	-38.88%
Sales	465.26M	P/S	5.15	EPS this Y	132.68%	Inst Trans	14.29%	Short Ratio	5.27	Perf Half Y	-35.97%
Book/sh	-1.37	P/B	-	EPS next Y	244.80%	ROA	-21.36%	Short Interest	0.79M	Perf Year	-40.75%
Cash/sh	0.17	P/C	46.59	EPS next 5Y	-	ROE	-	52W Range	7.35 - 14.76	Perf YTD	-39.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-30.68%	ROI	-31.54%	52W High	-46.21%	Beta	-0.01
Dividend TTM	-	Quick Ratio	1.69	Sales past 5Y	111.42%	Gross Margin	60.17%	52W Low	8.03%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	2.35	EPS Y/Y TTM	59.23%	Oper. Margin	9.23%	RSI (14)	29.94	Volatility	4.71% 6.55%
Employees	1032	Debt/Eq	-	Sales Y/Y TTM	408.85%	Profit Margin	-49.84%	Recom	2.00	Target Price	18.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	78.59%	Payout	-	Rel Volume	0.99	Prev Close	8.37
Sales Surprise	55.92%	EPS Surprise	-513.19%	Sales Q/Q	183.21%	Earnings	Mar 26 AMC	Avg Volume	150.78K	Price	7.94
SMA20	-8.22%	SMA50	-23.42%	SMA200	-32.10%	Trades		Volume	149,609	Change	-5.14%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-25	Initiated	UBS	Buy	$18
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $17
Oct-20-23	Upgrade	Citigroup	Sell → Neutral	$5 → $10
Sep-21-23	Initiated	Barclays	Equal Weight	$10
Sep-07-22	Initiated	Morgan Stanley	Equal-Weight	$10
Sep-06-22	Downgrade	Citigroup	Buy → Sell	$12 → $5
Jul-26-22	Initiated	Citigroup	Buy	$12

Apr-25-25 06:33AM	New Strong Sell Stocks for April 25th (Zacks) -5.14%
Apr-24-25 07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
Apr-17-25 05:27AM	New Strong Sell Stocks for April 17th (Zacks)
Mar-31-25 09:30AM	RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar (Zacks)
Mar-28-25 05:01PM	This Is a Test From GlobeNewswire (GlobeNewswire) -7.82%
12:09PM	Loading…
Mar-27-25 12:09PM	Alvotech (ALVO) Q4 2024 Earnings Call Transcript (SeekingAlpha) -10.30%
04:30AM	Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer (GlobeNewswire)
Mar-26-25 06:36PM	Alvotech Reports Record Results for 2024 and Provides Business Update (GlobeNewswire)
04:30AM	UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair (omalizumab) (GlobeNewswire)
Mar-20-25 04:09AM	Alvotech acquires Xbrane's R&D operations in Sweden and biosimilar candidate XB003 (SeekingAlpha)
03:00AM	Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production (GlobeNewswire)
Mar-19-25 11:13AM	FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review (Zacks)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Mar-18-25 08:35AM	Alvotech and Dr. Reddys Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva (Business Wire)
Mar-07-25 09:00AM	Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida (GlobeNewswire)
08:00AM	Loading…
Feb-24-25 08:00AM	Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET (GlobeNewswire)
Feb-21-25 06:00AM	Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S. (GlobeNewswire)
Feb-18-25 11:27AM	FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea (Investopedia)
06:00AM	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) (GlobeNewswire)
Jan-27-25 06:00AM	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi and Simponi Aria (golimumab) (GlobeNewswire)
Dec-23-24 04:00AM	Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 (GlobeNewswire) +5.12%
Nov-15-24 02:07AM	Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-13-24 04:05PM	Alvotech Reports Financial Results for the First Nine Months of 2024 (GlobeNewswire)
Nov-07-24 08:00AM	Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 (GlobeNewswire)
Nov-04-24 07:00AM	European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi (golimumab) (GlobeNewswire)
Oct-30-24 08:30AM	Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET (GlobeNewswire)
Oct-25-24 08:00AM	Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19 20, 2024 (GlobeNewswire)
Oct-22-24 07:00AM	Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara (ustekinumab) (GlobeNewswire)
Oct-10-24 05:01AM	European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva (GlobeNewswire)
Sep-25-24 05:01AM	Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio (GlobeNewswire)
09:15AM	Loading…
Aug-26-24 09:15AM	Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-24 04:15PM	Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 (GlobeNewswire) +7.96% +8.72%
04:30AM	European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) (GlobeNewswire)
Aug-01-24 04:02PM	Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET (GlobeNewswire)
Jul-22-24 06:35AM	STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe (GlobeNewswire)
Jul-11-24 04:45AM	Alvotech Announces Closing of Private Debt Financing (GlobeNewswire)
Jul-02-24 09:00AM	Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva (GlobeNewswire)
Jul-01-24 05:35PM	Alvotech Issues New Shares to Holders of Convertible Bonds (GlobeNewswire)
05:10AM	Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 (GlobeNewswire)
Jun-26-24 04:50AM	Alvotech Receives Conversion Notices for Majority of Convertible Bonds (GlobeNewswire) -5.87%
Jun-25-24 09:40AM	Are Medical Stocks Lagging Alvotech (ALVO) This Year? (Zacks)
Jun-24-24 09:23AM	Here's Why You Should Consider Buying Alvotech (ALVO) Stock (Zacks)
Jun-22-24 09:03AM	Did Teva Pharmaceutical Industries Limited (TEVA)'s Pivot to Growth Strategy Help It Get a Positive Rating from Analysts? (Insider Monkey)
Jun-18-24 04:01AM	Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea LD/HD in Europe (GlobeNewswire)
Jun-11-24 04:00AM	Alvotech and STADA add to Strategic Alliance through Denosumab Partnership (GlobeNewswire)
Jun-07-24 04:00AM	Alvotech Announces Strategic Refinancing Agreement (GlobeNewswire)
May-29-24 08:05AM	Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 (GlobeNewswire)
May-21-24 09:52PM	ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024 (InvestorPlace)
05:15PM	Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update (GlobeNewswire)
10:05AM	Alvotech and Dr. Reddys Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia & Xgeva in the U.S., Europe and UK (Business Wire)
07:55AM	Teva and Alvotech launch SIMLANDI in US for arthritis (Pharmaceutical Business Review)
May-20-24 08:25PM	Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S. (Business Wire)
May-15-24 09:30AM	Alvotech S.A. Annual General Meeting to be held June 7, 2024 (GlobeNewswire)
May-13-24 08:00AM	Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) (GlobeNewswire)
May-02-24 07:15AM	Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 (GlobeNewswire)
Apr-30-24 04:00AM	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab) (Business Wire)
Apr-24-24 04:00AM	Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi (golimumab) (GlobeNewswire)
Apr-19-24 06:10AM	Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira (adalimumab) (GlobeNewswire)
Apr-16-24 05:43PM	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) (Business Wire)
Apr-03-24 07:41AM	Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 (GlobeNewswire)
Mar-22-24 04:15PM	Alvotech Announces Increase in Number of Own Shares (GlobeNewswire) -11.24%
Mar-20-24 09:52PM	ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 (InvestorPlace)
04:15PM	Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET (GlobeNewswire)
Feb-29-24 04:05PM	Alvotech Appoints Interim Chief Quality Officer (GlobeNewswire)
Feb-26-24 09:58AM	TEVA Stock Pops 4% as Teva Receives FDA Approval (InvestorPlace) +7.74%
04:25AM	Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share (GlobeNewswire)
Feb-23-24 08:15PM	Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira (Business Wire)
Feb-15-24 06:30AM	Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara (ustekinumab) (GlobeNewswire)
Jan-29-24 04:00AM	Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva (GlobeNewswire)
Jan-22-24 10:03AM	Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates (Zacks)
Jan-19-24 11:30AM	Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 (GlobeNewswire) +15.29%
Jan-10-24 03:30AM	STADA and Alvotech secure approval for Uzpruvo, Europes first ustekinumab biosimilar to Stelara (GlobeNewswire)
Jan-03-24 03:30AM	Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea (aflibercept) (GlobeNewswire)
Dec-29-23 04:05AM	Biodexa Appoints Ann Merchant to the Board of Directors (GlobeNewswire)
Nov-29-23 04:00AM	Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria (GlobeNewswire)
Nov-28-23 04:15PM	Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update (GlobeNewswire)
04:15PM	Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update (GlobeNewswire)
Nov-21-23 08:00AM	Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET (GlobeNewswire)
Nov-14-23 07:00AM	Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara (ustekinumab) (GlobeNewswire)
Nov-10-23 09:30AM	STADA and Alvotech receive positive CHMP opinion for Europes first ustekinumab biosimilar to Stelara (GlobeNewswire)
Nov-07-23 08:00AM	Alvotech to Present at the Jefferies 2023 London Healthcare Conference (GlobeNewswire)
Oct-12-23 04:00AM	Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 (GlobeNewswire)
Oct-05-23 01:21PM	Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland (GlobeNewswire)
Oct-03-23 08:29AM	Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair (omalizumab) (Business Wire)
05:00AM	Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair (omalizumab) (GlobeNewswire)
Sep-25-23 04:00AM	Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara® (GlobeNewswire)
Sep-20-23 04:30AM	Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab) (GlobeNewswire)
Sep-11-23 05:00AM	Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-05-23 09:30AM	Alvotech Announces Changes to the Leadership Team (GlobeNewswire)
Aug-30-23 04:15PM	Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update (GlobeNewswire)
Aug-29-23 05:00AM	Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt (GlobeNewswire)
Aug-22-23 09:15AM	Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET (GlobeNewswire)
Jul-31-23 04:00AM	Alvotech Completes $100 Million Convertible Bond Private Placement (GlobeNewswire)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jul-24-23 04:00AM	Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership (GlobeNewswire)
Jul-06-23 07:26AM	Should You Exit Alvotech (ALVO)? (Insider Monkey)
Jun-28-23 07:00PM	Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02 (GlobeNewswire) -6.12%
Jun-12-23 07:00AM	Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara® (Business Wire) -9.51%
May-31-23 05:20AM	Alvotech to Participate in Jefferies Healthcare Conference (GlobeNewswire)

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Alvotech

Upgrade your FINVIZ experience